Achieve Life Sciences (ACHV) to Post Quarterly Earnings on Thursday

Achieve Life Sciences (NASDAQ:ACHV) is projected to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:30 AM ET.

Achieve Life Sciences (NASDAQ:ACHV) last posted its earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.11. On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Achieve Life Sciences Price Performance

NASDAQ:ACHV opened at $6.47 on Wednesday. Achieve Life Sciences has a 52 week low of $2.37 and a 52 week high of $7.11. The company has a quick ratio of 2.62, a current ratio of 2.62 and a debt-to-equity ratio of 0.87. The stock has a market capitalization of $664.21 million, a PE ratio of -5.78 and a beta of 2.24. The stock’s 50-day moving average price is $5.84 and its 200-day moving average price is $4.86.

Institutional Investors Weigh In On Achieve Life Sciences

Several institutional investors have recently bought and sold shares of ACHV. ADAR1 Capital Management LLC increased its stake in Achieve Life Sciences by 10.7% during the 3rd quarter. ADAR1 Capital Management LLC now owns 47,800 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 4,627 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Achieve Life Sciences by 39.9% in the second quarter. Bank of America Corp DE now owns 33,731 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 9,617 shares during the last quarter. AQR Capital Management LLC acquired a new stake in shares of Achieve Life Sciences in the first quarter worth approximately $32,000. Magnolia Capital Advisors LLC purchased a new stake in shares of Achieve Life Sciences during the fourth quarter worth approximately $64,000. Finally, State Street Corp increased its position in shares of Achieve Life Sciences by 6.3% during the fourth quarter. State Street Corp now owns 234,257 shares of the biopharmaceutical company’s stock worth $1,164,000 after purchasing an additional 13,873 shares in the last quarter. 33.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ACHV. UBS Group reiterated a “buy” rating on shares of Achieve Life Sciences in a research report on Tuesday, June 23rd. Raymond James Financial began coverage on Achieve Life Sciences in a research report on Friday, June 26th. They issued a “strong-buy” rating and a $20.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Achieve Life Sciences in a research note on Monday, June 22nd. Canaccord Genuity Group set a $13.00 target price on Achieve Life Sciences and gave the stock a “buy” rating in a research note on Monday, April 20th. Finally, Weiss Ratings upgraded Achieve Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $16.00.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.